Search Results
Apr 28, 2026, 03:55 ET Steele Honda Offers the Latest 2026 Honda CR-V Hybrid
road conditions. With refined handling and a quiet ride, the CR-V Hybrid delivers a comfortable, controlled driving experience, whether navigating city streets or cruising on highways. Drivers seeking more details about the 2026 Honda CR-V Hybrid can connect with the knowledgeable team at Steele
More news about: Steele Honda
Apr 27, 2026, 09:00 ET Crunch Franchise Brings State-of-the-Art Crunch 3.0 Gyms to Two Locations Across The Dallas-Fort Worth Area
to operate 18 total by the end of 2026. Its parent company, CR Fitness Holdings, is a leading Crunch Fitness franchisee that currently serves over one million members. Backed by major investment firms North Castle Partners and Sixth Street, CR Fitness is on track to operate 110 locations nationwide this
More news about: Crunch Fitness
Apr 24, 2026, 07:00 ET Lasfit: Redefining Vehicle Protection through GRS-Certified Safety and Precision Fit Car Mats
heavy cargo and extreme weather.A prime example of this Real-World Validation occurred with our SUV Seatback Protectors. When feedback from Honda CR-V owners revealed that standard Velcro could shift under heavy cargo, Lasfit immediately engineered a dual-layer security system with integrated lanyards.
More news about: LASFIT
Apr 24, 2026, 06:18 ET Ruijie Networks Gelar 2026 SBG APAC Channel Partner Summit di Chongqing; Luncurkan Merek SME Cybrey
berdasarkan arsitektur Cloud Edge Agentic Network (CEAN), Cybrey mengintegrasikan kapabilitas ACN, SSE, AIOps, NOC, dan UM. Portofolionya mencakup CF firewall, CR gateway, CAP access point, CS switch, dan Cybrey Cloud. Cybrey menghadirkan deployment 5x lebih cepat, menurunkan kompleksitas konfigurasi hingga 80%,
More news about: Ruijie Networks
Apr 24, 2026, 06:17 ET Ruijie Networks Tổ Chức Hội Nghị 2026 SBG APAC Channel Partner Summit Tại Trùng Khánh; Ra Mắt Thương Hiệu SME Cybrey
kiến trúc Cloud Edge Agentic Network (CEAN), Cybrey tích hợp các năng lực ACN, SSE, AIOps, NOC và UM. Danh mục sản phẩm bao gồm tường lửa CF, gateway CR, access point CAP, switch CS và Cybrey Cloud. Cybrey mang lại tốc độ triển khai nhanh gấp 5 lần, giảm 80% độ phức tạp cấu hình, đạt tỷ lệ xử lý sự cố
More news about: Ruijie Networks
Apr 23, 2026, 10:15 ET X-Ray Detectors Market worth $5.35 billion by 2031 | MarketsandMarkets™
market share during the forecast period.The global X-ray detectors market is segmented into flat-panel detectors (FPDs), computed radiography (CR) detectors, line scan detectors, charge-coupled device (CCD) detectors, and photon-counting detectors. The flat-panel detectors segment holds a leading
More news about: MarketsandMarkets
Apr 23, 2026, 03:00 ET MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
in the FL population, and the key secondary endpoints are PFS in the overall population as well as positron emission tomography complete response (PET-CR) and overall survival (OS) in the FL population.The clinical trial met its primary endpoint, with the data demonstrating a statistically significant
More news about: Specialised Therapeutics
Apr 21, 2026, 10:24 ET Tata Elxsi operating revenue at Rs. 993.8 Cr, registers healthy growth of 4.2% QoQ
reported operating revenue of Rs. 993.8 Cr. while the full year revenue was Rs. 3,757.4 Cr.Highlights of the Quarter Ended 31st March 2026:Revenues from operations at Rs. 993.8 Cr. compared to 953.5 Cr in Q3'26EBITDA at 244.6 Cr, growing 10.0% QoQ*; EBITDA Margin
More news about: Tata Elxsi
Apr 20, 2026, 22:10 ET Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile
– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed)– mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23%– No Grade 3 or higher adverse events related to RZ-001 observed– Highlights clinical potential of RNA trans-splicing ribozyme platform technology
More news about: Rznomics
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
high-dose groups, respectively. Complete metabolic responses (CMRs) were observed in both the medium- and high-dose cohorts, with a 100% complete response (CR) rate achieved in the high-dose cohort as updated by Professor Li Wang. Responses were seen across both aggressive (DLBCL) and indolent (FL, MCL, MZL)
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
high-dose groups, respectively. Complete metabolic responses (CMRs) were observed in both the medium- and high-dose cohorts, with a 100% complete response (CR) rate achieved in the high-dose cohort as updated by Professor Li Wang. Responses were seen across both aggressive (DLBCL) and indolent (FL, MCL, MZL)
More news about: Abogen
Apr 20, 2026, 09:00 ET Crunch Franchise Brings State-of-the-Art Crunch 3.0 Gym to Forney, Texas
Full-service locker rooms with showers and a dry sauna CR Fitness Holdings is a leading Crunch Fitness franchisee that currently serves over one million members. Backed by major investment firms North Castle Partners and Sixth Street, CR Fitness is on track to operate 110 locations nationwide this
More news about: Crunch Fitness
Apr 17, 2026, 16:01 ET New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
[24, 71]CR, n (%)7% (3/46) c
More news about: Nuvalent, Inc.
Apr 15, 2026, 09:03 ET Leading Crunch Franchisee Ignites Team Competition with High-Energy "Battle HIIT Out" Challenge
locations nationwide by the end of 2026.About CR Fitness Holdings CR Fitness Holdings is the leading and fastest growing franchisee of Crunch Fitness. CR Fitness currently serves over one million members, and is led by a management team with over 150 years of combined experience in
More news about: CR Fitness Holdings, LLC.
Apr 15, 2026, 07:27 ET Nuvoco Vistas Announces Strong FY26 Financial Results
maintaining an industry-leading level EBITDA increased by 35% YoY to reach Rs. 1,881 cr., driven by robust operational performanceProfit After Tax increased to Rs. 360 cr. from Rs 22 cr. in FY25 To set up a Bulk Terminal with a handling capacity of approx. 1.5 MMTPA
More news about: Nuvoco Vistas Corp. Ltd.
Apr 14, 2026, 17:57 ET UN TRIBUNAL FEDERAL DE ESTADOS UNIDOS DECLARA INOCENTE AL EMPRESARIO ALEX ROVIROSA EN UN HISTÓRICO RECHAZO A LA INFUNDADA ACUSACIÓN DEL DEPARTAMENTO DE JUSTICIA
Honorable Kenneth M. Hoyt, declaró hoy inocente a Alex Rovirosa de los cargos presentados en su contra en el caso United States v. Rovirosa, No. 4:25-cr-00415 (S.D. Tex.), liberando al empresario texano para que regrese con su esposa y su familia.
More news about: R McConnell Group PLLC
Apr 14, 2026, 17:23 ET U.S. DISTRICT COURT FINDS BUSINESSMAN ALEX ROVIROSA INNOCENT IN HISTORIC REBUKE OF DOJ'S BASELESS PROSECUTION
the Honorable Kenneth M. Hoyt presiding, today found Alex Rovirosa innocent of the charges brought against him in United States v. Rovirosa, No. 4:25-cr-00415 (S.D. Tex.), freeing the Texas businessman to return to his wife and family.
More news about: R McConnell Group PLLC
Apr 14, 2026, 03:49 ET CS Analytical Names Jennifer Roark to Director of Scientific Affairs
Europe. In 2021, Jen served on the AAMI TIB-WG04 – Elastomeric parts, components, and packaging committee, where she contributed to the drafting of CR514 Guidance for closed system transfer device (CSTD) testing with hazardous drugs. She serves as a US Expert Member for ISO TC 76/WG
More news about: CS Analytical
Apr 13, 2026, 10:33 ET Badanie DOORwaY90 firmy Sirtex Medical wskazuje na 100% miejscową kontrolę nowotworu przy pomocy SIR-Spheres®, ustanawiając nowy punkt odniesienia w zakresie terapii Y-90 w przypadku nieoperacyjnego raka wątrobowokomórkowego
DOORwaY90 osiągnęło wcześniej określone równorzędne pierwszorzędowe punkty końcowe, uzyskując wykazując 90% odsetek całkowitej odpowiedzi (CR) oraz najwyższy całkowity odsetek odpowiedzi (ORR) na poziomie 99% w oparciu o zaślepioną niezależną ocenę centralną. Wszyscy pacjenci kwalifikujący
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Sirtex Medical 的 DOORwaY90 研究表明，SIR-Spheres® 達成 100% 局部腫瘤控制，為肝細胞癌的 釔-90 療法樹立新基準
DOORwaY90 研究達到預先設定的共同主要終點，經盲法獨立中心審查評估，完全緩解率 (CR) 為 90%，最佳整體緩解率 (ORR) 為 99%。 所有可評估的患者均對治療產生反應，局部腫瘤控制率達到 100%，為釔-90 療法紀錄中最高的反應結果之一。 療效持久，75% 的療效持續超過六個月，中位數持續時間為 295 天，進一步證實 SIR-Spheres 釔-90 樹脂微球在維持肝功能同時提供持續腫瘤療效方面具有潛力。重要的是，超過
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
The DOORwaY90 study met its prespecified co-primary endpoints, demonstrating a 90% complete response (CR) rate and a best overall response rate (ORR) of 99%, as assessed by blinded independent central review. All evaluable patients responded to treatment,
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC
The DOORwaY90 study met its prespecified co-primary endpoints, demonstrating a 90% complete response (CR) rate and a best overall response rate (ORR) of 99%, as assessed by blinded independent central review. All evaluable patients responded to treatment,
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Štúdia DOORwaY90 spoločnosti Sirtex Medical preukazuje 100 % lokálnu kontrolu nádoru pomocou SIR-Spheres®, čím stanovuje nový štandard pri liečbe Y-90 hepatocelulárneho karcinómu
Štúdia DOORwaY90 splnila svoje vopred špecifikované primárne koncové ukazovatele, pričom preukázala 90 % mieru úplnej odpovede (CR) a najlepšiu celkovú mieru odpovede (ORR) 99 %, ako bolo stanovené zaslepeným nezávislým centrálnym hodnotením. Všetci hodnotiteľní pacienti reagovali
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Studie DOORwaY90 společnosti Sirtex Medical prokázala stoprocentní lokální kontrolu nádoru pomocí SIR-Spheres® a stanovila tak nový standard v léčbě HCC pomocí Y-90
Studie DOORwaY90 splnila předem stanovené společné primární cíle a prokázala devadesátiprocentní míru kompletní odezvy (CR) a nejlepší celkovou míru odezvy (ORR) ve výši 99 %, jak bylo hodnoceno v rámci zaslepeného nezávislého centrálního přezkumu. Všichni hodnotitelní pacienti
More news about: Sirtex Medical Inc.
Apr 13, 2026, 09:00 ET Studi DOORwaY90 dari Sirtex Medical Mendemonstrasikan Kontrol Tumor Lokal 100% dengan SIR-Spheres®, Menetapkan Tolok Ukur Baru di Y-90 untuk HCC
Studi DOORwaY90 memenuhi titik akhir ko-primer yang telah ditentukan sebelumnya, menunjukkan tingkat respons lengkap (CR) sebesar 90% dan tingkat respons objektif (ORR) terbaik sebesar 99%, sebagaimana dinilai oleh tinjauan pusat independen yang dibutakan. Semua pasien
More news about: Sirtex Medical Inc.